Reata to Present at FBR Capital Markets Spring Investor Conference

Presentation Scheduled for Thursday, May 29 at 2:00 EST

IRVING, TX -- May 27, 2008 -- Reata Pharmaceuticals, Inc. announces that its CEO, Warren Huff, will be presenting a company overview on Thursday, May 29, 2008 at the FBR Capital Markets 12^th Annual Spring Investor Conference.  This event is being held at the Grand Hyatt hotel in New York, New York. Mr. Huff's presentation is scheduled for 2:00 pm Eastern Time.  The presentation will focus on Reata’s two franchise technologies -- its AIM platform of novel, broad-spectrum anti-inflammatory agents and its protein folding discovery platform.  It will also highlight a number of upcoming Phase 2 data events with Reata's two lead compounds.

The company review will provide updated clinical data on RTA 402, an orally available, first-in-class Antioxidant Inflammation Modulator (AIM) in Phase 2 development for cancer, renal dysfunction, and autoimmune diseases.  This compound has produced highly promising results in early stage cancer trials, which were selected for oral presentation at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 1, 2008.  Mr. Huff will also share data demonstrating the potent and broad-spectrum activity of RTA 402 and other Reata AIMs in a series of high-value inflammatory indications.  An update will also be provided on berubicin (also known as RTA 744), a novel anthracycline in Phase 2 development for brain metastases.  Each of these drugs targets areas of substantial unmet medical need and has significant commercial potential.  Lastly, Mr. Huff will provide an update on the progress the company has made in identifying small molecule drugs that correct protein misfolding. 

About Reata

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases.  The company's two lead programs are in advanced clinical trials for deadly, late-stage cancers and proof of concept studies in inflammatory diseases.  In parallel with its clinical development, Reata is advancing a breakthrough drug discovery platform based around the use of small molecule molecular chaperones to correct protein misfolding. Reata takes a new and different approach to biotechnology, managing its pipeline as a portfolio of opportunities that can be advanced on a single management and physical infrastructure, streamlining the route to human trials and approval.   Founded in 2002, Reata is based in the Dallas area.  For more information, visit www.reatapharma.com.